Convert your targeting molecules into reporter-labeled probes and agents conjugated with IRDye® Infrared fluorophores.
Validate your dye-conjugated probes and targeted therapeutics in vitro and ex vivo with the Odyssey® CLx Imaging System or in vivo and ex vivo with the Pearl® Small Animal Imaging System.
Shape your targeting molecules into functionalized imaging probes and agents. Start with reporter dyes that get you sensitive and consistent detection for in vitro and in vivo use. If clinical translation is on your horizon, evaluate dyes with potential for human use.
Take your imaging probes and agents from bench to clinic with a versatile reporter dye technology.
IRDye Infrared Dye fluorophores provide exceptional sensitivity and high signal-to-noise ratios for detection and quantification. That’s because the IRDye advantage lies in near-infrared detection, where light absorption and autofluorescence of cellular and tissue components is low. So, imaging agents labeled with these fluorophores allow biochemical activity measurements of in vitro and in vivo assays with high-sensitivity.
But that’s not all. IRDye 800CW, 800BK, and 700DX fluorophores have found applications in preclinical and clinical use. Probes and agents conjugated to these dyes have propelled more than 20 Phase I and Phase II clinical trials worldwide.
“Among the fluorophores that we've used, the LI-COR dye, IRDye 800CW, seems to provide the ability to detect the tumors while maintaining suitable pharmacokinetics for use in vivo. It has worked quite well with our preclinical models.”
Assess the biological performance of your molecular probe or targeted therapeutic in vitro, in vivo, and ex vivo. Maximize your chances of success with a detection technology that will get you quantitative and consistent data.
Use one powerful detection technology for all your bioassays.
The Odyssey CLx Infrared Imaging System and the Pearl Trilogy Small Animal Imaging System provide an ideal near-infrared detection platform combination for complete analysis of the performance of your probe or targeted therapeutic in vitro, in vivo, and ex vivo.
Equipped with laser-based NIR detection, the versatile Odyssey CLx Imaging System platform allows accurate quantification of minute biochemical responses in a variety of assay formats. That means you can expedite the screening process for target specificity and binding affinity using higher throughput cell-based assays, such as the In-Cell Western™ and On-Cell Western assays.
With its 21 μm scanning resolution, the Odyssey CLx Imaging System lets you screen for probe or targeted therapeutics uptake, localization, and biodistribution in tissue sections and organs excised from treated animals. This facilitates macroscopic analysis without the need for an additional near-infrared microscope.
Engineered with single-camera optics and uniform illumination, the Pearl Trilogy provides an optimal imaging setup for small animal studies. The same laser-based NIR detection makes animal tissue virtually transparent, which aids greatly in tracking the biodistribution and clearance of probes or targeted therapeutics in vivo.
“Data from the Odyssey and Pearl Systems completely complement each other, which makes it easier to transition from cells to animals and back. We get more out of one animal compared to traditional methods.”
Your data is the foundation of your research discoveries. Get organized with Image Studio™ Software for acquiring, analyzing, quantifying, and archiving data images from LI-COR instruments.
Configured with a user-friendly ribbon-based interface, Image Studio lets you analyze and quantify validation data from micro-well plates, tissue sections, organs, and animals.
Get ready for clinical development of your imaging probes or targeted therapeutics. Team up with a research partner that understands your protocol development needs and research goals, and helps you achieve both.